8-K: Tactile Medical Reports Q1 2024 Results, Reaffirms Full Year Outlook

Tactile Medical announced its first quarter 2024 financial results, showing a 4% increase in total revenue and reaffirming its full-year 2024 revenue outlook.

Summary

• Tactile Medical reported a 4% year-over-year increase in total revenue for the first quarter of 2024, reaching $61.1 million, compared to $58.8 million in the first quarter of 2023.
• Lymphedema product revenue saw a 5% increase, while airway clearance product revenue decreased by 4%.
• The company experienced a net loss of $2.2 million, compared to a net loss of $1.9 million in the same quarter of the previous year.
• Adjusted EBITDA for the quarter was $1.0 million, up from $0.5 million in the first quarter of 2023.
• Gross profit increased by 5% to $43.4 million, with a gross margin of 71.1%.
• Operating expenses rose by 2% to $46.4 million.
• The company reaffirmed its full-year 2024 revenue outlook, expecting total revenue between $300 million and $305 million, representing a 9% to 11% year-over-year growth.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue growth, improved EBITDA, and reaffirmed outlook, but tempered by the net loss and slight decline in airway clearance revenue.

Positives

• Total revenue increased by 4% year-over-year, indicating growth in the business.
• Lymphedema product revenue saw a 5% increase, showing strength in this key product line.
• Adjusted EBITDA improved significantly to $1.0 million, demonstrating increased profitability.
• Gross profit increased by 5%, indicating improved efficiency.
• The company completed enrollment in a clinical trial for head and neck lymphedema, which could lead to future growth.
• A peer-reviewed study showed positive outcomes for Flexitouch use, supporting the product's effectiveness.
• The company reaffirmed its full-year 2024 revenue outlook, indicating confidence in future performance.

Negatives

• Airway clearance product revenue decreased by 4%, indicating a potential weakness in this product line.
• The company reported a net loss of $2.2 million, which is an increase from the $1.9 million loss in the same quarter of the previous year.
• Operating expenses increased by 2%, which could impact profitability.

Risks

• The company's ability to obtain reimbursement from third-party payers for its products is a risk.
• The impacts of inflation, rising interest rates, or a recession could negatively affect the company.
• Adverse economic conditions or intense competition could impact the company's performance.
• Price increases for supplies and components, as well as wage and component price inflation, are potential risks.
• The loss of a key supplier could disrupt operations.
• The entry of new competitors and products could impact market share.
• Compliance with and changes in government regulations pose a risk.
• The loss or retirement of key executives, including the CEO transition, could create uncertainty.
• Technological obsolescence of the company's products is a potential risk.
• Technical problems with the company's research and products could impact performance.
• The company's ability to expand its business through strategic acquisitions and integrate them successfully is a risk.
• The effects of current and future U.S. and foreign trade policy and tariff actions could impact the company.
• The inability to carry out research, development, and commercialization plans is a risk.

Future Outlook

The company continues to expect full year 2024 total revenue in the range of $300 million to $305 million, representing growth of approximately 9% to 11% year-over-year.

Management Comments

• We were pleased with our overall first quarter performance.
• Our lymphedema growth was in line with our expectations for the quarter, while sales of AffloVest were slightly ahead of expectations.
• We were also pleased to demonstrate continued increases in profitability and cash-generation.
• As we execute on our plans for 2024, we remain focused on driving improved operating efficiencies while advancing key tech-related investments, positioning us for sustained growth this year and beyond.

Industry Context

The results reflect the ongoing demand for at-home therapies for chronic conditions, a trend that is driving growth in the medical technology sector. The company's focus on lymphedema and airway clearance products aligns with the increasing prevalence of these conditions and the need for effective treatment options.

Comparison to Industry Standards

• Tactile Medical's 4% revenue growth is moderate compared to some high-growth medical device companies, but it is consistent with companies focused on chronic care.
• Companies like InMode (INMD) have shown higher growth rates, but they operate in different segments of the medical device market.
• The adjusted EBITDA improvement is a positive sign, as many medical device companies focus on profitability after initial growth phases.
• The company's gross margin of 71.1% is competitive within the medical device industry, where margins can vary widely based on product type and market position.
• Compared to companies like ResMed (RMD) in the respiratory care space, Tactile Medical's airway clearance segment is smaller and has shown a slight decline, indicating a need for strategic adjustments.

Management Changes

Stakeholder Impact

• Shareholders will be interested in the revenue growth and improved profitability, but may be concerned about the net loss.
• Employees may be affected by the CEO transition and the company's focus on operating efficiencies.
• Customers will benefit from the continued development and marketing of at-home therapies.
• Suppliers may be impacted by the company's focus on cost management.
• Creditors will be interested in the company's cash position and debt levels.

Next Steps

• Management will host a conference call on May 6, 2024, to discuss the results.
• The company will continue to execute on its plans for 2024, focusing on improved operating efficiencies and tech-related investments.
• The company will transition to a new CEO on July 1, 2024.

Key Dates

Keywords

Tactile Medical, Lymphedema, Airway Clearance, EBITDA, Revenue, Financial Results, Medical Technology, Flexitouch, AffloVest, Clinical Trial